| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 24 | 81.0x | 17.3x | Bottom tier | |
Growth | 55 | 10.4% | 7.1% | Around median | |
Quality | 97 | 21.2% | 4.5% | Top tier | |
Safety | 54 | 2.6x | 2.6x | Around median | |
Capital Return | 75 | 2.38% | 0.06% | Top tier | |
Momentum | 94 | 15.2% | -1.6% | Top tier | |
Sentiment | 66 | 19 | 3 | Top tier |
The floor: what the company is worth if growth stopped today
84% of today's price is what a buyer pays for growth that has not happened yet.
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
AbbVie develops and markets medicines across four main areas: immunology, neuroscience, oncology, and aesthetics. Its business mix relies on medicines such as SKYRIZI and RINVOQ in immunology, Vraylar, QLIPTA, and Vialev in neuroscience, VENCLEXTA and Epkinly in oncology, as well as Botox and Juvederm in aesthetics. The company derives growth from increased use of existing medicines, expanding their indications, launching new therapies, and adding drug assets through acquisitions.
In fiscal Q2 2026 ended 2026-06-30, revenue reached $17.0 billion, up 10.2% year over year from $15.4 billion in fiscal Q2 2025. Net income was $3.6 billion and diluted earnings per share were 2.03, while gross margin expanded to 74.7% from 71.8%, and operating margin rose to 37.9% from 31.7%. Immunology, particularly SKYRIZI and RINVOQ, led the business mix, supported by growth in the neuroscience portfolio, while oncology faced pressure from IMBRUVICA and aesthetics faced weakness in Juvederm.
During the last 12 months through 2026-06-30, AbbVie generated revenue of $64.4 billion, net income of $6.3 billion, operating cash flow of $19.5 billion, and free cash flow of $18.2 billion. In contrast, cash and investments totaled $6.6 billion versus total debt of $62.5 billion in fiscal Q2 2026. During the 90 days through 2026-09-27, one insider sold shares worth $8.2 million, all outside 10b5-1 plans, and no open-market purchases were recorded.
Q2 FY2026
Last 12 months to 2026-06-30
When: 2026-10-30
Fiscal Q3 2026 revenue at the $17.2 billion threshold
Annual revenue growth at the 10.2% threshold
Operating margin at the 37.9% threshold
The discounted cash flow model gives a value of $373 within a range of $289 to $512, and it measures the cash AbbVie is expected to generate using a discount rate of 8.8% and analysts' earnings estimates. The targets of 15 analysts place the median at $296 within a range of $235 to $315, pricing in growth expectations, while the industry multiple method gives $264 within a range of $220 to $331 by valuing the company like its peers based on a next-year earnings multiple of 17.3. The zero-growth value is $47 and measures what remains if current after-tax operating profit stays constant forever. Analyst targets and the industry multiple converge, while the discounted cash flow model is higher and has a wider range, and the zero-growth value falls sharply because it excludes any future expansion. Analyst targets tend to be optimistic by nature, while the discounted cash flow model tends to be conservative; the EL7 valuation pillar, at 21 out of 100 and ranked 50 out of 62 within the industry, adds comparative context for the valuation metrics.
Figures in the text are as of 2026-09-27; the live price is shown at the top of the page.
SKYRIZI and RINVOQ lead growth in immunology, and management expects global revenue of $21.7 billion for SKYRIZI in fiscal 2026. The neuroscience portfolio also relies on Vraylar, Botox Therapeutic, QLIPTA, and Vialev, with the addition of the Parkinson's disease treatment approved by the U.S. Food and Drug Administration on 2026-09-25. In fiscal Q2 2026 ended 2026-06-30, AbbVie's total revenue grew 10.2% to $17.0 billion despite biosimilar competition for HUMIRA.
AbbVie completed the acquisition on 2026-09-03 for $10.9 billion to expand its portfolio in dermatological and respiratory diseases. The added assets include zumilokibart for atopic dermatitis and APG273 for asthma, along with other programs for inflammatory diseases. The company maintained its fiscal 2026 adjusted earnings per share outlook of between $13.87 and $14.07, but it plans long-term financing and targets net leverage of 2x within two to three years of the transaction's closing.
Automated analysis for informational purposes only — not investment advice.
The U.S. Food and Drug Administration approved AbbVie's treatment for adults with Parkinson's disease on 2026-09-25, while the European Commission approved RINVOQ on 2026-09-22 for an indication in children aged two years and older. On 2026-09-03, etentamig recorded an objective response rate of 74% and reduced the risk of disease progression or death by 60% in the phase 3 CERVINO trial. The late-stage study announced on 2026-09-10 also met its primary endpoint for the prevention of menstrual migraine.
During the last 12 months through 2026-06-30, operating cash flow reached $19.5 billion versus net income of $6.3 billion, representing cash conversion equal to 309% of net income. Free cash flow reached $18.2 billion, while the company repurchased $1.5 billion of shares and recorded stock-based compensation of $976.0 million. This cash-generating capacity is set against a balance sheet containing $62.5 billion of debt and $6.6 billion of cash and investments in fiscal Q2 2026.
During the 90 days through 2026-09-27, one sale by one insider worth $8.2 million was recorded, and the seller was an executive. Sales executed under 10b5-1 plans totaled $0, while sales outside these plans totaled $8.2 million. No open-market purchases were recorded during the period, as purchases totaled $0.